Form 4 Filing for Aurinia Pharmaceuticals Inc. - Johnson Craig A

This filing details a Form 4 submission for Aurinia Pharmaceuticals Inc. by Craig A. Johnson, a director. On June 4, 2026, Johnson acquired 23,931 Director Stock Options to buy Common Shares, with an exercise price of $15.67 per share. These options vest one year from the date of grant and expire on June 4, 2036. The transaction code "A" indicates acquisition, and the ownership nature is direct. Following this transaction, Johnson directly owns 23,931 shares underlying these options. The filing was signed on June 8, 2026.